Pacira(PCRX)2025-02-27 21:06Financial Performance - Preliminary unaudited total revenue for 2024 is 675.0 million in 2023, representing a growth of approximately 3.7%[1] - Fourth quarter EXPAREL net product sales reached 143.9 million in 2023, indicating a growth of about 2.6%[3] - Full-year EXPAREL net product sales totaled 538.1 million in 2023, with average daily volume growth of 4%[10] - Full-year ZILRETTA net product sales were 111.1 million in 2023, reflecting a growth of approximately 6.3%[10] - The company reported a five percentage point gross margin improvement over 2024, indicating enhanced profitability[4] Strategic Objectives - The company aims to achieve five growth-oriented objectives by 2030 under its "5x30" plan, focusing on operational excellence and innovative non-opioid pain therapies[2] - The clinical pipeline is expanding with five novel programs currently in development, enhancing the company's growth potential[4] - The company is establishing five partnerships, including pipeline and commercial agreements, to bolster its market position[4] Product Development and Market Expansion - The company is focusing on the market acceptance and growth potential of EXPAREL, ZILRETTA, and iovera°, with plans to expand their use to additional indications[26] - The company is evaluating and developing additional product candidates utilizing its proprietary multivesicular liposome (pMVL) drug delivery technology[26] - The company is pursuing supplemental New Drug Applications and premarket notification 510(k)s with the U.S. Food and Drug Administration, as well as Marketing Authorization Applications with the European Medicines Agency[26] - The company is assessing its commercialization and marketing capabilities to enhance the success of its products[26] Future Reporting and Financial Guidance - Pacira plans to report complete financial results for the fourth quarter and full-year 2024 in the first quarter of 2025, along with financial guidance[6] Risk Management and Compliance - The company acknowledges known and unknown risks that could cause actual results to differ from forward-looking statements[27] - The company does not intend to update or revise forward-looking statements unless required by law[27] Operational Plans - The company is planning to complete capital projects and integrate any future acquisitions into its existing business[26] - The company is monitoring the recoverability of its deferred tax assets and assumptions related to contingent consideration payments[26] - The company anticipates funding or benefits from its share repurchase program[26]